Download Outcomes 2016 - Inova Heart and Vascular Institute

Inova Heart and Vascular Institute
Outcomes
2016
Outcomes
“The creation of a designated institute encompassing complex heart, vascular
and pulmonary medicine has allowed Inova to attract some of the field’s top
researchers and very best medical talent. This integration of expertise is having
a tremendous impact on the quality of care, not only within our facilities, but
across the region, the nation and beyond.”
Patrick Christiansen
Patrick Christiansen, PhD
Chief Executive Officer, Inova Fairfax Medical Campus
Executive Vice President, Inova
“Inova Heart and Vascular Institute’s continued enhancements in our service
offerings coupled with our growing involvement in cardiovascular research,
offer our patients the very best that this field of medicine has to offer.”
Heather Russell
Heather Russell, RN, MS, FABC
Administrator, Inova Heart and Vascular Institute
Vice President, Inova Fairfax Medical Campus
2016
Inova Heart and Vascular Institute
It has been my pleasure to oversee the continued growth and development of
Inova Heart and Vascular Institute (IHVI).
Working alongside Patrick Christiansen, PhD, CEO, Inova Fairfax Medical Campus and
EVP, Inova; Heather Russell, Administrator, IHVI and VP, Inova Fairfax Medical Campus;
and the medical, nursing and administrative leadership at each of our Inova hospitals,
tremendous progress is underway.
Our outcomes report reflects the results of those efforts. While much of IHVI’s patient
activity is centered at the flagship Inova Fairfax Medical Campus in Falls Church, VA,
development, program growth, and implementation of patient safety standards and processes to support
exceptional outcomes is actively underway across all hospital locations. The expanding scope and
geographic distribution of Inova Medical Group Cardiology (cardiology, arrhythmia, cardiac, thoracic
and vascular surgery) now encompasses 30 locations throughout Northern Virginia plus a Baltimore,
Maryland office.
Christopher O’Connor, MD
This past year also brought a tremendous surge in the amount of clinical research activity. We opened our
24-bed clinical trials unit and dedicated research laboratory, which are used to investigate novel therapies
and medical devices for a rapidly increasing number of Phase I – IV clinical trials. Our team published
over 220 peer-reviewed journal articles, multiple abstracts, contributed book chapters and presented
numerous papers and posters at national and international meetings. We have several physicians serving
in leadership roles through their national associations and specialty organizations.
Implementation of our pharmacogenomics research is evident in the availability of bedside genotyping
with one-hour test results to assure each patient undergoing cardiac catheterization immediately receives
the optimal anti-platelet drug and dosage amount. Initially available for catheterization patients at Inova
Fairfax Medical Campus, testing will be available soon at every Inova hospital. We also anticipate use of
the test to expand beyond the Cath Lab to all cardiovascular disease patients taking clopidogrel. Later
this year, we’ll be introducing a cardiovascular genomic test called HealthyHeartMap™ which provides a
genomic-based risk profile.
Our day-to-day performance for delivery of patient care enjoyed several bright spots this year – from
above average patient experience ratings to performance measures placing us among the top performing
hospitals nationwide in acute myocardial infarction, interventional cardiology and cardiac surgery.
Multiple programs earned or continued to maintain stellar performance recognized by various program
certifications, quality rankings and program designations.
In short, our journey to become a Top 10 cardiovascular and lung center continues and it is a thrill to be
part of this very exciting journey.
Christopher O’Connor, MD, FACC, FESC, FHFSA
Chief Executive Officer
Inova Heart and Vascular Institute
1
Table of Contents
Cardiac Diagnostics and Catheterization . . . . 11
Opening Comments . . . . . . . . . . . . . . . 1
About Us . . . . . . . . . . . . . . . . . . . . . 2
Patient Experience, Outcomes and Safety . . .4
Cardiac Research . . . . . . . . . . . . . . . . 6
Interventional Cardiology . . . . . . . . . . . .. .12
Electrophysiology . . . . . . . . . . . . . . . . 17
Cardiothoracic Surgery and Services . . . . . . 18
Vascular Surgery . . . . . . . . . . . . . . . . . 26
Pulmonary and Vascular Disease. . . . . . . . .28
Inova Heart and Vascular Institute Service Sites
2
Inova Fairfax Medical Campus
3300 Gallows Road
Falls Church, VA 22042
Inova Alexandria Hospital
4320 Seminary Road
Alexandria, VA 22304
Inova Fairfax Medical
Campus (IFMC) is the
flagship campus for
Inova Heart and Vascular
Institute encompassing a
dedicated heart hospital,
Inova Cardiovascular Genomics Center and Inova
Thrombosis Research and Drug Development
Center which includes a dedicated 24-bed Clinical
Trials Unit for Phase I – IV studies. Capabilities
cover the full spectrum of complex cardiovascular
and pulmonary care. Services offered include
cardiac diagnostic services, cardiac imaging,
cardiac catheterization, interventional cardiology,
electrophysiology, cardiothoracic surgery and
complex airway interventions, vascular surgery,
vascular and interventional radiology, advanced
lung disease and transplant program, cardiac
and respiratory failure program, heart failure and
transplant program and cardiac rehab.
Capabilities include
vascular and
interventional radiology,
cardiac catheterization,
electrophysiology,
cardiovascular magnetic
resonance imaging and cardiac surgery. In
addition to procedural areas with six interventional
labs, we offer non-invasive vascular and cardiac
diagnostic services together with a long-standing
cardiopulmonary rehabilitation program.
Healthgrades 2016 Distinguished Hospital
Award for Clinical Excellence™ *
Healthgrades 2016, 2015 America’s 100
Best Hospitals for Stroke Care Award™*
Inova Fair Oaks Hospital
3600 Joseph Siewick Drive
Fairfax, VA 22033
Capabilities include
vascular and
interventional radiology
(IR), non-invasive vascular
and cardiac diagnostic
services including
echocardiography, cardiac stress testing and
peripheral vascular ultrasound.
Healthgrades 2016, 2015 Distinguished Hospital Award
for Clinical Excellence™ *
About Us
6
Cardiac Surgery ORs
23
34,992
2016 Patient Visits
5
Hospitals
Catheterization
EP/IR Labs
1
Hybrid OR
209
Dedicated
Cardiac Beds
48
Patients treated from
states and
Territories/Foreign Countries
8
Cardiac and Respiratory Failure. . . . . . . . . . . 30
Inova Heart and Vascular Physicians
. . . . . . . .38
Heart Failure. . . . . . . . . . . . . . . . . . . . . . 32
IHVI Physician Leadership Development Program . .40
Cardiac Rehab . . . . . . . . . . . . . . . . . . . . 36
Inova at a Glance . . . . . . . . . . . . . . . . . . . .40
Women and Heart Disease . . . . . . . . . . . . . 36
IHVI Center for Learning and Innovation. . . . . . . 37
Publications . . . . . . . . . . . . . . . . . . . . . . 37
Schaufeld Family Heart Center
Inova Loudoun Hospital
44045 Riverside Parkway
Leesburg, VA 20176
Inova Mount Vernon Hospital
2501 Parkers Lane
Alexandria, VA 22306
Cardiovascular
capabilities include full
spectrum interventional
radiology and vascular
services, cardiac
catheterization,
electrophysiology, diagnostic testing and imaging
including cardiac CT, cardiac nuclear medicine,
echocardiography, and ultrasound. In addition to the
procedural areas with three interventional labs, we
also offer non-invasive cardiac diagnostic services
and cardiac and pulmonary rehabilitation programs.
Capabilities include
vascular surgery and
interventional radiology
(IR), cardiovascular
magnetic resonance, and
emergent pacemaker
placement. In addition to procedural areas and
interventional labs, we offer non-invasive
vascular and cardiac diagnostic services and
a cardiopulmonary rehabilitation program.
Other inpatient and outpatient diagnostic services
include echocardiography and stress testing.
Healthgrades 2016, 2015 Distinguished Hospital
Award for Clinical Excellence™ *
3
Schaufeld Family Heart Center Expansion
In November 2016, Inova Loudoun Hospital
announced a historic $5 million commitment
from the Schaufeld family to support the
physical expansion and programmatic growth
of IHVI’s Schaufeld Family Heart Center.
The gift will also help fund community
education around cardiovascular health.
30+
Inova Medical Group cardiology,
arrhythmia, cardiac and thoracic surgery
and vascular practices in the
Northern Virginia and Maryland area.
This represents the largest cash gift to Inova
Loudoun Hospital and the largest single
contribution to IHVI’s cardiac care services.
Enhancements and additions to the
Schaufeld Family Heart Center will
take place in two phases.
Learn more at inova.org/schaufeldpr
HEALTHGRADES*
Consumer Choice
identifies hospitals that have
superior clinical performance
and patient outcomes
2016/2017 #1 ranking as “Washington
DC’s Most Preferred Hospital for
Overall Quality and Image”
NRC Health – Market Insights Survey
(IFMC awarded 17 times)
Patient Experience, Outcomes and Safety
“Through their unique experiences, these past patients and family members
advise and provide perspective on programs, policies, services, and other
issues that impact care, ensuring that the next patient or family member’s
journey is easier.”
Merdod Ghafouri, DO, FACC, FAHA
Chief Patient Experience Officer, IHVI
Merdod Ghafouri, DO
Director, Inova Center for Learning and Innovation
IHVI Patient and Family Advisory Council
The Centers for Medicare and Medicaid Services
require hospitals that treat Medicare patients to
participate in the national Hospital Consumer
Assessment of Healthcare Providers and Systems
(HCAHPS) survey, a standardized tool that measures
patients’ perspectives of hospital care. The Patient and Family Advisory Council (PFAC)
partners former Inova Heart and Vascular Institute
patients and families with members of our healthcare
team to provide guidance and support on how to
improve the patient and family experience. Patients
and families have been invited to serve as part of this
hospital committee to ensure that the patient’s point
of view, perspective, and experience are not only
heard, but also integrated into the service and quality
improvements that are engineered to ensure highquality, patient-centered care.
HCAHPS Domains of Care
IHVI
4
National Average
78.6%
Hospital Rating
(9 or 10) 0 - 10 Scale
72.4%
82.5%
Recommend the Hospital
(% Definitely Yes)
73.7%
For a list of PFAC Council members, see page 37.
79.4%
Nurse Communication
80%
62%
Responsiveness of
Hospital Staff
66.4%
HCAHPS Top Box Ratings
78.8%
Doctor Communication
IHVI
National Average
81.3%
66.5%
Hospital Environment
66.6%
80
Pain Management
84.4
82.5
78.6
72.4
72.6%
2016
2015
100
73.7
78.4
73.3
74.1
60
71.9%
40
60.9%
New Medications
Communication
20
64.2%
0
86.5%
Discharge Information
87.2%
58.8%
Care Transition
53.4%
0
20
40
60
80
100
Hospital Rating
(9 or 10) 0 - 10 Scale
Recommend the Hospital
(% Definitely Yes)
Hospital Rating
(9 or 10) 0 - 10 Scale
Recommend the Hospital
(% Definitely Yes)
Quality Outcomes and Patient Safety
At Inova Heart and Vascular Institute, we
embrace continuous monitoring of quality
outcomes and patient safety. Throughout
this report and as part of our ongoing efforts,
we utilize our internal data and national
registries as benchmark comparisons for
our performance. Every patient care unit has
identified specific performance metrics where
progress and performance is clearly displayed
to keep staff focused on these indicators and
results produced.
Multispecialty teams comprised of nurses,
physicians, IT specialists, finance experts and
data analysts work to monitor performance
and redesign processes to improve care for
patients. This past year, we focused efforts
on patients treated for NSTEMI and patients
undergoing valve replacement surgery to
optimize clinical effectiveness by embedding
best practice guidelines to improve outcomes,
maximize efficiency and decrease cost.
“The ability to benchmark our
performance is a powerful
tool which drives our clinical
improvement efforts.”
Harvey Sherber, MD, FACC
Medical Director, IHVI
Harvey Sherber, MD
For a list of outcomes team members,
see page 37.
“Great teamwork and
communication support our
journey to prevent errors and
improve care. Outstanding
communication is critical to
ensuring patient safety.”
Charles Murphy, MD
Charles E. Murphy, MD, CPPS
Chief Patient Safety Officer, IHVI
In 2016, Inova Fairfax Medical Campus (IFMC)
experienced a reduction in total harm to patients of
22 percent - inclusive of a 30% reduction in
C diff infections, 50% reduction in Venous
Thrombo-embolism, and a 30% reduction in
falls. In fact, harm per 1,000 patients discharged
has been consistently lower every month as
Scott Betzelos, MD
compared to 2015, with the lowest rate of 19/1,000
patients discharged in December 2016. This is a testament to
the extraordinary work being done by our talented staff whose
dedication to patient safety is unmatched.
At the center of our mission here at IFMC is a commitment to
improve the health of the diverse community we serve through
excellence in patient care, education, research and a profound
impatience for patient harm. We methodically and deliberately
examine opportunities to improve patient care and outcomes every
time, every touch. Our commitment to Zero Harm is contiguous
with our journey to become a High Reliability Organization (HRO),
building a Just Culture and training our entire organization in
TeamSTEPPS.
In the spirit of HROs, IFMC deploys systems that achieve
outcomes through design rather than practice thereby avoiding
potentially catastrophic errors. A committee of hospital leadership
and provider staff meets consistently to strategically and reliably
implement HRO principles across the organization. This same
committee recognizes and supports process standardization with
clinical variation reduction that has been proven to lower morbidity,
mortality and outcome disparity.
We implemented strategies throughout 2016 to engage staff on the
principles that are foundational to an HRO. These principles include:
1. Preoccupation with Failure
4. Sensitivity to Operations
2. Deference to Expertise
5. Reluctance to Simplify
3. Commitment to Resilience
In May 2016, The Joint Commission conducted a full assessment
of IFMC’s HRO readiness. Their results found that we are in a
more advanced stage in our journey to become an HRO than the
average hospital. We ranked high in areas such as Physicians,
Quality Strategy, Culture Assessment and Management; we have
opportunities in the area of Systems Strengthening, Performance
Improvement Methodologies and Information Technology.
We have implemented tactics campus-wide to support our journey.
These include an evolving and robust cause analysis program, safety
check-ins where representatives from each area come together
daily to discuss and follow up on safety events, measurement of our
culture of safety through an annual survey and shared governance
through our Nursing Practice Congress.
We remain steadfast in our commitment to High Reliability
Outcomes, Just Culture development and TeamSTEPPS to
achieve Zero Harm.
Scott Betzelos, MD, MS, MBA
Vice President, Chief Medical Officer, Inova Fairfax Medical Campus
Associate System Chief Medical Officer, Care Coordination, Inova
5
Cardiac Research - Leading Edge Care
“IHVI research experienced exponential growth in 2016 with rapid expansion
of its site based research and inclusion of a new large outpatient base.
The academic success of IHVI can also be summarized by the volume of
peer reviewed publications from a diverse and successful faculty.”
Christopher deFilippi, MD, FACC
Vice Chairman, Academic Affairs, Inova Heart and Vascular Insitute
Christopher deFilippi, MD
Inova Cardiovascular Genomics Center
A Precise Approach to Improving Management of
Cardiovascular Disease
Through this program we are able to evaluate for
genetic abnormalities in a variety of genes associated
with common cardiovascular conditions such as:
• Familial Hypercholesterolemia
Key to our ability to provide high-quality
cardiovascular care is integrating precise diagnostics
and therapeutics into the routine care of
cardiovascular patients.
6
To that end, Inova Cardiovascular Genomics Center
was co-developed with the Division of Medical
Genomics at the Inova Translational Medicine Institute
and is focused on integrating cutting edge genomics
into the clinical care of cardiovascular patients.
Goals of the center are to:
• Assist a patient’s primary cardiologist or
physician to diagnose, educate and manage
patients with genetic cardiovascular disorders,
and
• Explore alternative pioneering genomic
approaches that improve management
of patients with established cardiovascular
disease.
We have developed a comprehensive cardiovascular
genomics program that brings the promise of
personalized medicine to the patient. This begins
with a traditional cardiovascular genetics program
that provides genetic counseling and targeted
genetic testing for individuals with possibly inherited
cardiovascular disease.
• Dilated Cardiomyopathy
• Sudden Cardiac Arrest
• Hypertrophic Cardiomyopathy
• Marfan’s Syndrome
We are the only program in the DC metropolitan area
that is truly a multidisciplinary clinic of cardiologists,
genetic counselors, and researchers. Additionally,
our team of medical geneticists, molecular biologists
and bioinformaticists help distinguish variants of
undetermined significance to make more precise
genetic calls for our patients.
Our consultations provide detailed clinical
recommendations about the genetic findings to
help a patient’s primary cardiologist or physician
determine the best course of action and to act as
a partner in the ongoing care of these complex
patients. We can support the patients’ healthcare
team to the degree needed.
“Through the incorporation of precise
genomic testing we are maximizing the
cardiovascular health of our patients and
their families.”
Palak Shah, MD, MS, FACC
Director, Cardiovascular Genomics
Palak Shah, MD
Contact Us I Refer A Patient
Inova Cardiovascular Genomics Center
1.855.5CVGENES (1.855.528.4363) • inovaheart.org/cvgenomics
It is important to note that many cardiovascular
conditions have an autosomal dominant inheritance
pattern, meaning up to 50% of family members
may be affected. We take a family approach to
managing patients that includes pre-test counseling
that outlines the implications of testing for the
patient and family. In families who choose not to be
tested, we outline a plan for non-genetic screening
that is consistent with clinical practice guidelines.
For those families that elect to be tested, we
provide results in an easy to understand format to
the patient, family and provider along with detailed
management recommendations.
Pharmacogenomics Testing
We go beyond the traditional genetics program
to incorporate pharmacogenomics, which
allows for identification of genes that result in
abnormal absorption, distribution, metabolism or
excretion of commonly prescribed cardiovascular
pharmacotherapies. The pharmacogenomics
service also works in real-time to manage patients
with cardiovascular disease in the hospital setting,
through point-of-care testing for CYP2C19 MediMap Clopidogrel STAT™. CYP2C19 is a
gene that has been associated with abnormal
metabolism of clopidogrel (Plavix®) leading to
increased risk of cardiovascular events in patients
with reduced gene activity.
HealthyHeartMap™
Cardiovascular Genomic-based Risk Profile
We are working with outside collaborators
to develop a cardiovascular genomic-based
risk profile, HealthyHeartMap™ that will risk
stratify healthy patients for cardiovascular risk,
based on genetic markers or polymorphisms.
This test, expected to be available in the second
half of 2017, will provide additive information
to commonly considered cardiovascular risk
factors (e.g., age, sex, blood pressure, cholesterol)
used in the Atherosclerotic Cardiovascular Disease
(ASCVD) calculator.
7
Cardiovascular and Pulmonary Research
Areas of Study:
Advanced Heart Failure
Cardiology
Cardiovascular Disease
Cardiovascular Surgery
Electrophysiology/Heart Rhythm
Interventional Cardiology
Pulmonary Disease and Transplant
8
-
Idiopathic Pulmonary Fibrosis
Interstitial Lung Disease
Interventional Pulmonology
Lung and Heart Transplant
Other Advanced Lung Diseases
Pulmonary Hypertension
Sarcoidosis
Scleroderma and Interstitial Lung Disease
Structural Studies of the Heart
Thrombosis
Vascular
For a complete list of
currently enrolling studies, visit
inovaheart.org/research
“Providing rapid, on-demand genetic and platelet function testing is an important
component in our ongoing quest for more personalized antithrombotic therapy.
We are excited about utilizing our expertise and novel technologies to advance
our efforts and improve outcomes in high risk patients.”
Paul A. Gurbel, MD
Paul A. Gurbel, MD
Director, Inova Thrombosis Research and Drug Development Center
Director, Interventional Cardiology and Cardiovascular Medicine Research, IHVI
Professor of Medicine, Johns Hopkins School of Medicine
Adjunct Professor of Medicine, Duke University School of Medicine
Inova Thrombosis Research and Drug Development Center
Inova’s Thrombosis Research and Drug
Development Center is partnering with
pharmaceutical and medical device companies to
investigate novel therapies that are likely to guide
the future of interventions and treatment. Through
the work of some of the top cardiovascular and
pulmonary physician leaders and researchers,
we are focused on improving outcomes through
personalized medicine.
Under the direction of Paul A. Gurbel, MD, a
renowned international expert in the field of
cardiovascular research and antithrombotic therapy,
the center focuses on antiplatelet and anticoagulant
drug development and device development to
facilitate personalized therapy.
Thrombosis Lab
• 4,000 sq. ft. lab meets GLCP standards
• Pharmacodynamic, pharmacokinetic and
genetic studies
• Antiplatelet and anticoagulant drug
development
• Device studies for 510K approval
• Device development to facilitate
personalized therapy
• Biobanking capabilities
• Onsite processing for ready analysis,
24/7 stat results
Housed within IHVI on Inova Fairfax Medical
Campus, the center is equipped with a
state-of-the-art research laboratory, located in close
proximity to IHVI’s cardiac catheterization labs,
and a dedicated 24-bed Clinical Trials Unit where
pharmacodynamic, pharmacokinetic, and genetic
studies are conducted. Together, these unique
characteristics grant the center the capacity to
conduct the most intricate investigations of platelet
physiology and coagulation in a diverse population
of patients with cardiovascular disease and to
collectively manage clinical trials in all Phases,
I through IV, for both inpatients and outpatients.
inovaheart.org/trialswebvideo
9
Clinical Trials Unit
• 24-bed unit offering all private rooms located
at IHVI - IFMC
- Acute care availability for emergencies
- Adjacent to cath labs and thrombosis
clinic
• Research pharmacy based on the unit,
capable of IV and oral preparations
• Hospital nurses and staff with specialized
research training
• Experienced clinical research coordinators
and research staff, including a regulatory
specialist
• Capable of using local or central IRB’s
• Inova Translational Medicine Institute and
Inova Cardiovascular Genomics Center
• Bio-banking repository for oncology, liver,
heart and lung
• Active heart and lung transplant programs
Contact Us l Refer a Patient
1.877.654.6682 • [email protected]
10
Diagnostics and Catheterization
Cardiac Diagnostics
IHVI is building a leading edge clinical diagnostics
program staffed by imaging experts offering in-depth
knowledge of all major modalities for advanced
cardiac diagnostic services.
“Our goal is to provide the highest standard of clinical
expertise by using subspecialists in each area of
imaging. The concentrated volume of studies and
level of personal expertise, combined with a collegial
approach in working with the other cardiothoracic
services, has increased the quality of imaging and
interpretations. We provide a resource of consultative
expertise to cardiologists and other specialists.”
Cardiac Diagnostic Procedures - 2016
Facility
Transesophageal Transthoracic
Echocardiogram
Echo
(TEE)
(TTE)
IFMC
1,467
Cardiac
Nuclear
Studies
Graded
Exercise
Test (GXT)
1, 136
664
11,920
IAH
233
4,318
1,131
1,189
ILH
169
2,513
1,316
1,326
IMVH
216
1,958
882
697
IFOH
106
5,052
356
N/A
IHVI Total
2,191
25,761
4,821
3,876
Pamela Sears-Rogan, MD
11
Medical Director, Cardiac Imaging
Cardiac Catheterization
Our outpatient cardiac catheterization program
remains one of the busiest in the region, blending
multidisciplinary expertise with convenient patient
access including a dedicated interventional
cardiology admission area.
Diagnostic Cardiac Catheterization
Facility
2014
2015
2016
IFMC
3,284
3,262
3,404
IAH
680
939
1,046
ILH
589
621
665
4,553
4,822
5,115
IHVI Combined
Interventional Cardiology
Acute Myocardial Infarction (AMI)
Sustained Achievement of Performance Measures
Door-to-Balloon Median Time for Non-Transfer Patients
2012 - 2016
IHVI
IHVI provides consistent high performance in the
area of Acute Myocardial Infarction (AMI) with
adherence to current guidelines – which translates
to better patient outcomes including lower short-term
and long-term mortality.
The program’s success is due to great teamwork
among physicians, nurses and technical staff and
coordination throughout the Inova system and across
patient care areas including the Cardiac Cath Lab,
Cardiac Care Unit, Progressive Cardiac Care Unit,
Cardiac Rehab and Emergency Department,
area EMS services and referring hospitals.
12
Our process improvement efforts focus on a target
Door to Balloon (D2b) time of 60 minutes, exceeding
the CMS D2b target of 90 minutes, which we have
consistently achieved in nearly 100% of patients.
Primary PCI Received Within 90 Minutes
IHVI
Combined
100
97.1%
93.5%
60
60
60
60
59
59
60
40
20
59
56
50
55
2012 2013
2014
2015
STEMI Volume Combined
Non Transfer
Patients
Transfer
Patients
500
300
99
200
264
121
113
302
315
2015
2016
100
2014
2015
2016*
* Source is 2016 Q2 NCDR CATH/PCI Outcomes Report
(with rolling 4 quarters)

4-Star rating: ACC/NCDR
Cath/PCI Registry
59
57
400
80
0
70
NCDR Like
Hospitals
96.7% 93.6% 96.4% 95.9%
NCDR Like Vol Hospitals
0
2014
2016
Percutaneous Coronary Interventions
2015 and 2016 ACC/NCDR Cath/PCI
Registry awarded its highest possible
rating (4 Stars) for use of all recommended medications,
to reduce the chance of blood clots and decrease
cholesterol after PCI/Angioplasty.
PCI Success
• Our PCI in-hospital risk-adjusted mortality rate
places us in the Top 10% for PCI in-hospital
risk adjusted mortality for all patients with PCI.
• Our PCI in-hospital risk-adjusted mortality rate
for patients with STEMI places us in the
Top 10% for PCI in-hospital risk adjusted
mortality for STEMI patients with PCI.
99.1% 99.0%
99.3% 98.9%
2014
2015
98.1% 98.1%
80
60
40
20
0
2016 *
* Source is 2016 Q2 NCDR CATH/PCI Outcomes Report
(with rolling 4 quarters)
NCDR Like Hospitals
IHVI Combined
3.0
100
PCI Volume - IHVI Combined
Composite Score
3.5
NCDR Like Hospitals
IHVI Combined

3.2%
2.8%
2.7%
2.7%
2.9%
2014
2015
2016
1,705
1,816
1,900
2.4%
2.5
13
2.0
1.5
1.0
0.5
0.0
2014
2015
2016 *
Composite Score includes death, emergency
CABG, stroke, repeat target vascularization
“Inova offers the best in coordinated cardiovascular care in the region. Our outcomes for
acutely ill patients are among the best in the country due to a highly skilled and dedicated
staff of physicians, nurses and technicians. Our system is linked so that patients with more
complex conditions are rapidly transported to Inova Fairfax Medical Campus for advanced
care including management of patients requiring emergency surgery and management of
cardiogenic shock which requires specialized care and equipment.”
Nicholas Cossa, MD
Nicholas Cossa, MD, FACC
Medical Director, Cardiac Cath Lab and Level 1 Emergency Cardiac Care
Percutaneous Coronary Interventions cont.
PCI Risk Adjusted Mortality for All Patients - 2016*
1.5
1.25
1.32
1.28
1.12
1.2
IFMC Distribution of Performance
0.9
10TH
Percentile
3.23
0.6
Chronic Total Occlusion (CTO)
0.3
Symptomatic Relief thru PCI
0.0
CTO is present in 15 to 30 percent of patients
undergoing coronary angiography.
Traditionally, it has been one of the main
reasons patients are sent for coronary
bypass surgery. Yet, almost a third of these
patients do not get re-vascularized at the
time of surgery.
14
Successful CTO intervention in the
appropriate patient alleviates the need for
open heart surgery and can offer significant
relief of anginal symptoms and improvement
in left ventricular function. Our experience
has demonstrated an 84% success rate for
Q1 through Q3 in 2016.
IHVI is at the forefront of this complex PCI
technique and has proven expertise as
one of the largest CTO programs in the
Mid-Atlantic region.
Our experience has demonstrated an
84% success rate for Q1 - Q3 in 2016.
90TH
Percentile
1.07
50TH
Percentile
1.97
1.32
IAH IFMC ILH IHVI
(Weighted)
PCI Risk Adjusted Mortality (STEMI) - 2016*
3.86
4.0
3.24
3.5
3.0
3.53
2.84
IFMC Distribution of Performance
2.5
2.0
10TH
Percentile
1.5
12.18
50TH
Percentile
6.64
90TH
Percentile
3.72
1.0
0.5
0.0
3.86
IAH IFMC ILH IHVI
(Weighted)
PCI Risk Adjusted Mortality (excluding STEMI) - 2016*
1.0
0.8
0.82
0.75
0.84
0.78
IFMC Distribution of Performance
84%
81%
CTO Procedural
Success Rates
0.6
10TH
Percentile
2.16
0.4
0.2
0.0
0.75
IAH IFMC ILH IHVI
(Weighted)
* Source is 2016 Q2 NCDR CATH/PCI Outcomes Report
2016
2015
50TH
Percentile
1.01
(with rolling 4 quarters)
90TH
Percentile
0.49
Structural Heart: Valve Disease/Surgery
Less Invasive Techniques for All Risk Levels
Trans Aortic Valve Replacement (TAVR)
Catheter-based Aortic Valve Treatments
Trans Aortic Valve Replacement (TAVR) has
revolutionized treatment of aortic stenosis, offering
a minimally invasive alternative to open aortic valve
replacement surgery. TAVR is currently available
commercially for patients at moderate or high risk
for complications following surgical aortic valve
replacement. TAVR treatment is also available for
low risk patients at Inova as part of a nationwide,
multi-center clinical trial. IHVI’s program is one of
the busiest in the state of Virginia and in the
Washington, DC metropolitan area.
Stroke Risk Reduction
• State-of-the-art hybrid operating room
where cardiac surgeons, cardiologists and
electrophysiologists operate together.
• Access to four different valves (two
commercial, two investigational) to treat
almost all patients regardless of anatomy.
• Unique experience in alternative access
without invading the chest which helps reduce
LOS and morbidity.
• Robust involvement in research to treat
different patient populations.
- Unload Trial (patients with moderate risk
and heart failure)
- Galileo to optimize therapy post-TAVR
(anticoagulation vs. antiplatelet therapy)
- Partners III Trial (TAVR for treatment of
severe symptomatic aortic stenosis in
patients at low risk for heart surgery)
• Only program in DC Metro area that is part of
a multi-center trial comparing TAVR to SAVR in
low risk patients.
Watchman® Left Atrial Appendage Closure Device
This procedure is indicated for stroke risk reduction
in non-valvular atrial fibrillation patients who are
not candidates for chronic anticoagulation due to
noncompliance, occupational restrictions, long-term
bleeding risk or a strong preference not to take
anticoagulants. Following placement performed in
the cath lab and an overnight stay, patients can be
discharged home with anticoagulation permanently
discontinued after 45 days.
2016 Watchman Procedures:
34
Mitral Valve Repair
MitraClip® Transcatheter
This procedure is indicated for people with
significant symptomatic degenerative mitral
regurgitation (MR>3+) who are not candidates for
open mitral valve surgery due to prohibitive risk.
Placed using a minimally invasive catheter-based
approach and real-time imaging, the MitraClip
grasps and coapts the mitral valve leaflets, resulting
in fixed approximation of the leaflets throughout
the cardiac cycle. MitraClip allows for real-time
MR reduction assessment and repositioning, if
necessary, to ensure the best possible outcome.
Patients generally are discharged home within
three days.
2016 MitraClip Procedures:
• Applying TAVR principles to high risk/
prohibitive surgical patients with mitral disease.
6
- Valve in MAC as well as valve in ring TMVR
• Dedicated coordinators and mid-level
practitioners to help patients navigate through
pre-procedural work-up and post-procedural
follow-up.
TAVR Procedures:
2014
2015
2016
63
63
170
Shawn Yazdani, MD,
FACC, FSCAI
Co-director
Structural Heart
Disease Program
Eric Sarin, MD
Co-director
Structural Heart
Disease Program
Contact Us I Refer A Patient:
703.776.3135 • [email protected]
15
16
Electrophysiology
Atrial Fibrillation (AF)
Cardiac Rhythms Disorders
IHVI is proud to have participated in the pre-FDA
approval study of the cryoballoon, STOP-AF.
Data from IHVI and this study provided the basis
for FDA approval of an ablation modality that is
quickly increasing in usage for paroxysmal AF
in the United States. IHVI remains in the top 1
percentile of cryoballoon usage in the United
States. Cryoballoon uses freezing energy,
rather than heat, to isolate those areas of the heart
responsible for the initiation of atrial fibrillation.
The electrophysiologists at IHVI continue to use
ablation strategies and devices that are at the
leading edge of arrhythmia therapy:
For patients with persistent atrial fibrillation and
atrial fibrillation that does not stop by itself,
modalities include pulmonary vein isolation, and
ablation of other foci that participate in how AF
sustains. IHVI is a leader in the use of FIRM rotor
mapping for patients in whom pulmonary vein
isolation alone has not worked.
IHVI has been the source of many publications
regarding the effectiveness of the surgical MAZE
procedure for AF. AF surgery can be done
both in conjunction with other cardiac surgical
procedures, or as a “mini-Maze”, a minimally
invasive technique for isolated AF.
• Epicardial ablation for when the critical focus
causing arrhythmia is coming from the outside,
not the inside, surface of the heart.
• IHVI is a site for pre-FDA approval of the
leadless pacemaker, which requires no leads
and no surgical pocket.
• Highest EP volume in the DC Metro region.
• Hybrid OR for procedures that require advanced
mapping and electrical recording capabilities of
an EP lab with the resources of a cardiac OR.
• FIRM mapping and ablation procedures used
at IFMC are performed only at select referral
centers nationwide. IHVI is the only site in the
DC metropolitan region.
Device Implant Volumes
IHVI Combined
Pacemaker
Concomitant Cox Maze Procedures
Stand-Alone Cox Maze Procedure
Concomitant Left Atrial Ablation
2015
2016
969
898
926
559
603
613
Biventricular
265
256
254
Dual and Single Chamber
339
357
305
143
293
400
2015
2016
ICD’s
Atrial Fibrillation Surgery
2014
Loop Recorder
7
2014
Electrophysiology Data
33
76
IHVI Combined
4
2015
75
2014
35
6
2016
0
60
20
25
40
60
80
100
120
Electrophysiology Studies
848
887
840
Ablation Procedures (Total)
955
1024
1314
AV node Ablation
155
126
547
SVT Ablation
496
504
145
VT Ablation
96
55
86
209
286
464
23
42
51
Afib (including Radiofrequency
and Cryo)
Laser Device Lead Extraction
Procedures
17
Cardiothoracic Surgery and Services
Coronary Artery Bypass Grafting
“In the last 35 years I have never been more excited about new investigative and
technological advances not only in cardiac surgery but in thoracic surgery, vascular
surgery, electrophysiology, heart failure and interventional cardiology. The IHVI
environment drives multidisciplinary cooperation with rapid implementation of leading
edge treatments to improve patient care and outcomes.”
Alan Speir, MD
Medical Director, Cardiac Surgical Services
Alan Speir, MD
CABG Mortality
2009 - 2016
CABG Readmission Within 30 Days
2011 - 2016
2.5%
2.0
12
2.0
2.0
2.0
1.7%
18
2.0
10.4%
2.0
1.6%
2.1%
9.91%
10
1.7%
8
1.5
7.55%
1.2%
1%
1.0
1%
.97%
5.5%
2011
.5%
0.5
7.3%
7.77%
6
4
0.0
STS Benchmark
IHVI
2.5
2012
2013
2014
2015
.3%
2009 2010
2011
IHVI
2012
2013 2014
STS Benchmark
2015
2016
2016 - Partial Year
CABG and CABG Combined Volume
2014 - 2016
Isolated CABG
CABG and Mitral Valve Replacement
CABG and Aortic Valve Replacement
500
The Society of Thoracic Surgeons awarded
IHVI its highest rating for the quality of Coronary
Artery Bypass Surgery in the current analysis of 2015
national data. Approximately 12-15% of hospitals nationwide
achieve this highest quality tier.
400
52
5
18
393
40
382
2014
2015
6
CABG and Mitral Valve Repair
CABG and Carotid
7
13
4
43
414
300
200
100
0
STS
NationalDatabase
TM
Participant 2016
2016
2016 - Partial Year
STS highest rating for quality of
Coronary Artery Bypass Surgery
2016
6
5
9
Valve Disease Surgery
Valve Disease Volume and Stats
2014
2015
2016
Isolated Aortic Valve Replacement
89
103
95
Isolated Mitral Valve Replacement
20
21
17
Isolated Mitral Repair
58
78
35
Total Valve Volume
503
526
546
Isolated Valve Surgery Mortality
Valve Surgeries
Mortalities
2014
2015
2016
167
202
147
1
1
1
Post-Op Blood Products Used
Post-Op Blood Products Used
50
IHVI
STS Benchmark
40
19
30
20
10
0
2011
2012
2013
2014
2015
2016
Intra-Op Blood Products Used
Intra-Op Blood Products Used
50
IHVI
STS Benchmark
40
30
20
10
0
2011
2012
2013
2014
2015
2016
20
16
Cardiothoracic Surgery and Services cont.
Pediatric Congenital Heart Program
Caring for the children of the Mid-Atlantic region has
been the focus of the Congenital Heart Program at Inova
Children’s Hospital for over 25 years, and the opening
of our new, expanded Inova Children’s Hospital in early
2016 reinforced this commitment. The new, 226-bed
hospital features all private pediatric rooms, including
an 8-bed Pediatric Cardiovascular Intensive Care Unit
(within a larger 26-bed Pediatric ICU), and a 22-bed
Pediatric Cardiac and Intermediate Care Unit. Each
room was built with ECMO and bedside cardiac surgical
procedures in mind.
In addition, the Fetal Care Center at Inova Children’s
Hospital provides expert diagnosis and a coordinated
delivery and care plan to pregnant women who are at
risk or suspected of carrying a baby with a congenital
heart defect. The center provides a full continuum of
care by combining the expertise of Inova Women’s
Hospital with highly specialized neonatologists and
pediatric subspecialists of Inova Children’s Hospital.
“The Congenital Heart
Program at Inova
Children’s Hospital
provides a total scope
of services, even for the
tiniest of patients.
Our multi-disciplinary
Lucas Collazo, MD
team of specialists work
together to provide the highest level of
care possible which allows for better
patient outcomes. The seamless integration
we offer with both Inova Women’s Hospital
and Inova Heart and Vascular Institute
allow for patients to receive care in a
single location, providing a better patient
experience for patients and their families.”
Lucas Collazo, MD
Medical Director
Pediatric and Congenital Cardiac Surgery
21
Pediatric Surgical Mortality
IHVI
5
4
STAT
4.1%
3.9%
4.1%
3.3%
3
3%
2.7%
2%
2
1.75%
1.4%
1
.4%
0
2011
2012
2013
2014
In 2016, Inova and Children’s
National Health System announced
a collaborative effort to improve the
quality and availability of comprehensive
cardiovascular care for children in
Northern Virginia and throughout
the greater DC region, pledging to
significantly enhance value, outcomes,
access and experience for parents and
children with cardiac diseases.
2015
Contact Us I Refer a Patient:
One Call
24/7 Admission. Transfer. Specialized Transport.
1.877.900.9543
Pediatric Interventional Catheterizations by Type
2013 - 2015
PDA
Coil
ASD
Septostomy
Pediatric Electrophysiology Procedures by Type
2013 - 2015
Balloon Dilation
Hybrid
Melody
ICD
7
36
23
59
33
3 10
3
35
5
20
30
73
60
49
2015
90
1
4
1
25
3
120
10
20
30
40
50
60
150
Pediatric Cardiac Cathertizations Volume
2013 - 2015
Type
6
2
0
0
58
5
16
2014
43
41
EP
2
12
2015
11
2013
11
2014
Ablation
1
01
2013
Pacemaker
Pediatric Congenital Heart Surgery Volume
2013 - 2015
2013
2014
2015
2013
2014
2015
Pediatric Interventional
132
95
130
Type
Pediatric Open
128
100
89
Pediatric Diagnostic
82
70
59
Pediatric Closed
116
108
80
22
Volume and Survival by Surgical Procedure: 2013 - 2015
Surgical Procedure
2013
Volume
2013
Survival
2014
Volume
2014
Survival
2015
Volume
2015
Survival
20
100%
15
100%
10
100%
Tetralogy of Fallot (TOF)
5
100%
7
100%
8
88%
Atrial Septal Defect (ASD)
8
100%
3
100%
8
100%
Arterial Switch for TGA
7
100%
8
88%
2
100%
Ventricular Septal Defect (VSD)
26
100%
17
100%
18
100%
Atrioventricular Canal Repair (AVC)
3
100%
9
100%
8
100%
Total Anomalous Pulmonary Venous Return (TAPVR)
3
100%
3
66%
4
100%
Partial Anomalous Pulmonary Venous Return (PAPVR)
4
100%
2
100%
4
100%
Caval Pulmonary Connections (Glenns and Fontans)
16
100%
11
73%
10
80%
Coarctation of the Aorta
10
100%
8
100%
12
100%
Systemic-Pulmonary Shunt
4
100%
3
100%
8
100%
Pacemakers and ICDs (primary and replacements)
9
100%
11
100%
10
100%
Norwood/ Damus-Kaye-Stansel/Hybrids
8
100%
5
80%
1
100%
ECMO Support
5
80%
6
33%
1
0%
Valves/Conduits
70
80
“We provide a needed service for this unique population, and the collaboration
among the adult and pediatric physicians of our team at the Adult Congenital
Clinic enhances care in a very important way.”
Pradeep Nayak, MD, FACC, FASE
Medical Co-Director
Inova Adult Congenital Heart Program
Pradeep Nayak, MD
Adult Congenital Heart Program
Congenital and Pediatric Cardiac Catheterizations
For over 20 years, dedicated adult and pediatric
cardiologists, surgeons and nurses at the Inova
Adult Congenital Heart Clinic have served our
community as part of this unique program.
Patients have access to the full breadth of
cardiovascular services, including our pulmonary
hypertension, advanced heart failure, cardiac
surgery and transplant programs.
150
Interventional
Diagnostic
132
Adult
130
120
103
95
90
82
89
88
70
59
60
Many patients have survived to adulthood
following complex childhood cardiac surgery.
These individuals require lifelong specialized care.
Others grow up with undiscovered congenital heart
disease and require surgical or catheter-based
intervention as adults.
30
0
2014
2013
2015
23
Congenital Cardiac Catheterizations and
Heart Surgery Volume (Adult): 2013 - 2015
Type
2013
2014
2015
Adult Congenital
51
34
38
Adult Interventional and Diagnostic
103
89
88
Adult Congenital Operations
(due to congenital heart disease)
Adult Congenital Operation
Adult Congenital Interventional Cath by Type
Diagnostic
ASD
Melody Valve
Balloon Dilations/
Noncoronary Stents
100
2013
2014
2015
ASD
5
9
5
AVR
6
3
6
MVR
1
1
3
PVR
5
3
3
PAPVR
1
4
2
Other
29
14
17
88
80
57
60
40
31
22
20
5
0
56
52
2013
12
1
2014
5
4
9
2015
Contact Us I Refer A Patient:
Adult Congenital Heart Program
703.776.3599
Thoracic Services
“The collaboration of interventional pulmonology and thoracic surgery offers optimal
diagnostic and therapeutic options to patients
with lung disease.”
Sandeep Khandhar, MD, FACS
Medical Director, Thoracic Surgery
Sandeep Khandhar, MD
Few programs integrate interventional pulmonology and
thoracic surgery to the degree available at IHVI-IFMC.
Our sub-specialized experts offer a rare combination of
talents and work in a coordinated fashion to generate exceptional outcomes for patients while employing the latest
in minimally invasive techniques.
24
One IHVI thoracic initiative -- WAVE (Walking After VATS
Experiment) – has garnered international attention for
bringing a multidisciplinary approach to early ambulation
after thoracic surgery. The first six years’ data, presented
at IASLC, revealed that aggressive early ambulation is
effective in reducing post-operative complications and
shortening length of stay.
The team’s involvement with industry for device and
process development delivers leading edge technology
and techniques for our patients.
Diagnosis and Treatment of Complex Airway
and Pleural Disease
The Interventional Pulmonary team, comprised of Amit
Mahajan, MD, FCCP, DAABIP, respiratory therapists
Shazia Khan RT, Manju Parne RT, and Kimberly Pullen
RT pride themselves on a multidisciplinary approach to
the treatment of complex airway and pleural disease
including lung cancer as well as non-malignant diseases
of the chest. Working together with thoracic surgeons,
oncologists, and radiation oncologists they devise a
personalized plan of care for each patient. They work
to offer the most leading edge therapies and strive to
improve patient care by offering their expertise in the
expeditious diagnosis and management of complex airway,
lung and pleural disease.
The comprehensive service offering includes participation
in numerous clinical trials aimed at advancing pulmonary
medicine. Learn more at inovaheart.org/research
Contact Us l Refer a Patient:
Thoracic Services
703.280.5858
Conditions treated:
• Lung cancer
• Lung nodules
Thoracic Services Procedure Total
• Airway obstructions
2015
2016
• Airway stenosis
1,529
1,686
• Airway malacia
• Complications following lung transplant
• Enlarged lymph nodes
Thoracic Surgery Procedures 2015 - 2016
• Foreign body removal
Procedure Type
2015
2016
Dx/Rx non-anatomic
233
229
Lobectomy
80
85
• Lung cancer
• Pleural effusions (cancerous and non-cancerous)
Procedures performed:
Pneumonectomy
2
3
• Argon plasma coagulation
Chest Wall Resection
2
2
Tracheal resection
1
1
• Bronchial thermoplasty
Esophagectomy
17
8
Other Esophageal
33
28
Mediastinal
28
39
Minor
29
22
• Electromagnetic navigation bronchoscopy
Total
425
417
• Endobronchial ultrasound bronchoscopy
• Chest tube placement
•Cryotherapy
•Electrocautery
• Fiducial marker placement
• Flexible and rigid bronchoscopy
Interventional Pulmonology Patients
and Procedures: 2015 - 2016
Patients treated
Rigid bronchoscopy
• Intrabronchial valve placement
• Laser therapy
• Medical thorascopy/pleuroscopy
2015
2016
827
932
61
111
• Photodynamic therapy
• Percutaneous tracheostomy
Flexible bronchoscopy
241
312
• Stent placement
Endobronchial ultrasound bronchoscopy
284
279
•Thoracentesis
Electromagnetic navigation bronchoscopy
125
114
Airway stent placement
25
46
• Tunneled pleural catheter placement
Endobronchial laser/electrocautery
41
57
Endobronchial cryotherapy/cryodebridement
27
38
Chest tube
66
83
Thoracentesis
114
87
Tunneled pleural catheter placement
51
45
Fiducial placement
24
27
Percutaneous tracheostomy
11
25
Intrabronchial valve
5
8
Endobronchial balloon dilation
29
37
Total
1,104
1,269
• Whole lung lavage
“We have revolutionized how
we approach complex airway,
pleural disease and especially
lung cancer through minimally
invasive diagnostic and
therapeutic techniques. We
strive to provide patients
Amit Mahajan, MD
comprehensive care while
recognizing that interventions must be
performed effectively and expeditiously.”
Amit “Bobby” Mahajan, MD, FCCP, DAABIP
Medical Director, Interventional Pulmonology
WAVE (Walking After VATS Experiment)
Hiran “Chrish” Fernando, MD
joins thoracic surgery team
in 2017
25
Vascular Surgery
“We’re doing more than just saving a leg. We’re improving and extending a life.”
Richard Neville, MD, FACS
Associate Director, IHVI and Director, Vascular Services
Richard Neville, MD
Inova Heart and Vascular Institute is a referral center
for vascular disease including complex aortic and lower
extremity revascularization procedures. Inpatients
are cared for on a dedicated vascular unit. Our team
consists of internationally recognized specialists who
offer comprehensive diagnostic and treatment options
for vascular disease – from medical management
and rehabilitative therapies to minimally invasive
endovascular and/or open surgical procedures.
• Complex diagnostic tests and treatment regimens
26
• Ultrasound technology to diagnose carotid artery
disease to prevent stroke, detect decreased
blood flow to the legs to prevent amputation
and to diagnose abdominal aortic aneurysms
• State of the art open surgical procedures
involving carotid disease, lower extremity bypass,
aortic aneurysms and varicose vein procedures
• Comprehensive endovascular therapies to
provide minimally invasive treatment for vascular
disorders
• Non-invasive diagnostic vascular laboratory for
the screening, diagnoses and follow-up services
for individuals with possible or existing vascular
conditions
Our clinicians are active at the national level, providing
presentations at vascular meetings, invited lectures,
visiting professorships, and through publication of
manuscripts, abstracts, book chapters, and serving
on editorial review and scientific advisory boards.
IHVI also offers only one of three Limb Fellowship
programs in the U.S. for physicians interested in
specializing in limb preservation.
Contact Us I Refer A Patient
IHVI Vascular Services
703.207.7007
Limb Preservation Program
Multifaceted Expertise in Wound Care,
Revascularization, and Rehabilitation
Amputation and wound healing is a problem for
an increasing number of patients, especially those
suffering from diabetes, renal failure and the
complex problem of Peripheral Arterial Disease
(PAD). Our program brings together a group of
specialists that allows us to combine minimallyinvasive endovascular techniques with the latest
bypass procedures to streamline the treatment
process and improve outcomes.
The goal is to prevent amputation and enhance
healing in complex scenarios by restoring arterial
circulation. We also include aggressive medical
therapy to manage chronic diseases to prevent
future complications.
Treatment Options
The IHVI team is dedicated to providing ease
of access to a wide variety of treatment options
including state of the art clinical trials and a full
range of services:
• Vascular lab
• Endovascular therapy
• All facets of advanced wound care
• Hyperbaric oxygen therapy
This approach to limb preservation incorporates
revascularization, rehabilitation and clinical trials
that advance the field of knowledge and lead to
new therapies. Integration within IHVI provides
patients cardiovascular care that addresses the
overlap between PAD and cardiac care.
1 of 3
Limb Fellowship programs in the U.S.
Conditions:
Treatments:
• Abdominal aortic aneurysm
• Aortic aneurysm
- Open (conventional) aneurysm repair
- Endovascular repair (EVAR)
- Thoracic endovascular aneurysm repair
(TEVAR)
• Amputation prevention
• Aortic dissection
• Carotid artery disease
•Claudication
• Carotid disease
- Carotid endarterectomy
- Carotid stent angioplasty
• Critical limb ischemia
• Deep vein thrombosis (DVT)
• Diabetic foot
•Lymphedema
• Mesenteric ischemia
• Peripheral artery disease
• Renal artery disease
• Lower extremity revascularization
- Endovascular therapy
• Angioplasty
• Stenting (drug elution technology)
- Bypass surgery
• Traditional
• Minimally invasive
• Thoracic aortic aneurysm
• Thrombolytic therapy
• Varicose veins
• Dialysis access
• Venous insufficiency
• Venous disease
- Endovenous ablation
- Surgical vein stripping
27
Vascular Surgery - 2016
Procedure
Procedure Detail
IFMC
IFOH
IAH
IMVH
ILH
IHVI
Total
Carotid
Carotid Artery Stent
Carotid Endarterectomy
2
-
-
24
123
48
13
2
1
187
48
15
2
1
211
54
10
3
-
-
67
Open AAA Repair
5
1
1
-
-
7
Thoracic Endovascular Aneurysm Repair
25
-
-
-
-
25
84
11
4
-
-
99
Endovascular AAA Repair
Aneurysm Total
Peripheral Arterial Disease
-
145
Carotid Total
Aneurysm
22
Peripheral Vascular Intervention
174
17
53
15
55
314
Bypass (comb. Supra and Infra)
74
25
8
7
-
114
248
42
61
22
55
428
Hemodialysis Access
78
188
18
14
-
298
IVC Filter
193
35
40
37
36
341
Lower Extremity Amputation
32
7
16
6
3
64
Other Vascular Total
303
230
74
57
39
703
Vascular Total
780
331
154
81
95
1,441
Peripheral Arterial Disease Total
Other Vascular
Pulmonary and Vascular Disease
Advanced Lung Disease and Transplant Program
A Leader In Lung Disease Treatment And Transplantation
Lung Transplantation
IHVI offers comprehensive care for patients with any form of
advanced lung disease as well as the DC metro area’s only lung
transplantation program. 2016 marked the 25th anniversary of the
lung transplant program with over 400 lung transplants having
been performed to date.
Lung Transplant Volume
2014
2015
2016
27
19
21
Disease Transplanted
Other Interstitial
Lung Disease
28
Bronchiolitis
or Retransplant
Bronchiectasis 3
Connective Tissue Disease
54
88
COPD
9
29
11
50
Sarcoid
Alpha 1 Antitrypsin
Deficiency
149
Idiopathic
Pulmonary
Fibrosis
Lymphangioleiomyomatosis 8
19
Cystic Fibrosis
Pulmonary Hypertension 6
One Year Survival Rates
Observed
Expected
Adult Graft Survival
90.05
85.90
Adult Patient Survival
89.71
87.36
According to the most recent Scientific Registry for Transplant Recipients
(SRTR) report, one-year survival rates are as expected.
Contact Us I Refer A Patient
703.776.6168
“I am especially proud of the programs we have established and the cutting edge care
we provide to patients. The fact that 20 percent of our new evaluations travel more
than 100 miles to IHVI for the program services and seven percent live more than 200
miles away, attests to our standing as a regional and national referral center.”
Steven Nathan, MD, FCCP
Medical Director, Advanced Lung Disease and Lung Transplant Program
Steven Nathan, MD
Advanced Lung Disease Program
Complementing the Lung Transplant Program
is the Advanced Lung Disease Program which
offers the only Pulmonary Fibrosis Foundation
Care Center Network Site and the only
Pulmonary Hypertension Association accredited
Comprehensive Care Center in the Washington,
DC area. These accreditations signify top-level
outcomes and experience with highly specialized
advanced care options.
The program offers a blend of clinical expertise,
outstanding education and robust research
productivity. Pulmonary fellows from all academic
institutions in the DC metro area and southern
Virginia rotate through the program. The program
follows nearly 1300 patients in total:
Patients Followed*
* Patients qualified as being followed if they were seen twice
in a 12-month span.
Interstitial lung disease
606
Inova Fairfax Medical Campus’ Pulmonary Vascular
Disease Program is the largest program in the
DC/Metropolitan area and the state of Virginia.
COPD
107
Pulmonary hypertension
356
Bronchiectasis
92
Inova’s Advanced Lung Disease and Transplant
Program is one of 67 CMS accredited lung
transplant centers. In addition, it is one of 35
accredited Comprehensive Care Centers for
Pulmonary Hypertension, one of 44 Pulmonary
Fibrosis Foundation Care Centers and is
designated as an Alpha-1 Antitrypsin Deficiency
Clinical Resource Center by the Alpha-1
Foundation. As of January 2017, the adult and
pediatric programs were designated a CF Care
Center by the Cystic Fibrosis Foundation. This
makes Inova’s program one of only seven centers
in the country to hold all four designations.
Lung transplant
125
Our integrated program offers a unique paradigm
for treatment of patients with diverse forms of
advanced lung disease, some, but not all of whom,
might require lung transplantation in the future.
This unique model of care, which encourages
a cross fertilization of expertise and personnel
across clinics, differentiates the program from
many others where a “siloed” approach to distinct
patient populations exists.
The clinical care team is comprised of physicians,
nurses, pharmacists and respiratory therapists, and
is supported by a robust rehabilitation service.
New advances underway:
• Clinical research bio-repository and early drug
development – allowing access to advanced
therapeutic options through clinical trials
including an implantable pump system (under
review by the FDA) for administration of
intravenous treprostinil.
• Establishment of a dedicated Chronic
Thromboembolic Disease Pulmonary
Hypertension Program (CTEPH)
Lung Listing:
2014
2015
2016
35
27
34
2014
2015
2016
Referrals:
484
558
540
Evaluations:
361
373
335
1 of 7centers
in U.S. to hold all
4 designations
Cystic Fibrosis Foundation
CF Care Center
29
Cardiac and Respiratory Failure
ECMO (Extracorporeal Membrane Oxygenation)
Neonatal, Pediatric and Adult
“CF Care Center accreditation is a testament
to the multi-disciplinary care that our program
provides. We look forward to engaging with
the Cystic Fibrosis Foundation on continued
research endeavors, as we strive toward new
treatments for the disease.”
James Clayton, MD
Medical Director, Pediatric Cystic Fibrosis Program
and Pediatric Lung and Allergy Center
30
Inova Children’s Hospital
Pediatric Lung and Allergy Center
Each year more than 1,000 new cases of cystic
fibrosis are diagnosed in the U.S., the majority
of which occur in children under the age of 2.
Because of advances in treatment driven by the
Cystic Fibrosis Foundation, the life expectancy
for children diagnosed with CF has drastically
increased in recent decades. Today, more than
half of those living with CF are over the age of 18.
The Cystic Fibrosis Center at IFMC is a combined
effort of the Advanced Lung Disease Program and
Inova Children’s Hospital, in partnership with the
Inova Pediatric Lung and Allergy Center.
Inova Children’s Hospital offers a team approach
to the care of cystic fibrosis patients. While most
care occurs outside the hospital, inpatient care
is provided in the Inova Children’s Hospital Level
IV NICU, PICU and pediatric inpatient units.
Outpatient services for children are provided
at the Pediatric Lung and Allergy Center,
a division of Fairfax Neonatal Associates, P.C.
The Pediatric Lung and Allergy Center has been
an affiliate site of the Cystic Fibrosis Foundation
for the past several years and, as of 2017, is
designated as a CF Care Center by the Cystic
Fibrosis Foundation.
ECMO (Extracorporeal Membrane Oxygenation) provides
temporary mechanical support to patients with severe cardiac
and/or respiratory failure.
We support patients from newborn through adult.
In 2016, we provided over 14,000 hours of life support
for 67 patients, a six-fold increase from prior years.
Survival rates for resuscitation from cardiac arrest, pneumonia,
heart attack, bridge to lung transplant and post transplant are
above the national average.
Our team of on-site specialists are in-house 24/7. They are led
by clinicians with over 25 years of experience and expertise
in ECMO. Our fully dedicated bedside team provides patients
exceptional clinical care and avoids stress on ICU staff focused
on other aspects of the patient’s care. Therapy is tailored to
best support each patient’s needs. In addition to ECMO, we
also provide other forms of mechanical support such as Impella,
ventricular assist, and tandem heart.
Referring physicians participate in a phone conference with the
ECMO physician, surgeon and other members of the team as part
of the intake process. We also provide daily updates and return
patients to their local environment as soon as medically possible.
We developed a venovenous ECMO program for
12 patients with primary respiratory disease and
bridge to lung transplant.
ECMO Survival - Primary Respiratory Disease and
Bridge to Lung Transplant
80
ECMO Survival for Venovenous and Venoarterial
% IHVI Survival Rate
% Survival - National
80
70
67%
58%
60
50
73%
37%
40
70
41%
30
20
56%
60
10
50
0
40
30
12 Patients
54 Patients
Venovenous
ECMO program
Venoarterial
ECMO
20
10
0
IHVI Survival
National Average
We supported over 50 venoarterial ECMO patients with
cardiac arrest, myocardial infarction, pulmonary embolus,
postoperative heart surgery, shock from infection, trauma,
heat stroke and other underlying causes.
Our team pioneered awake and walking ECMO. In 2017,
equipment expansion will allow us to support up to eight
ECMO patients.
Working with Inova Thrombosis Research and Drug
Development Center, we are performing leading edge
research to help eliminate the major complications of
bleeding and thrombosis.
Impella Volume
Impella 2.5
Impella CP
Impelle 5.0/RP
80
70
60
14
50
40
44
30
20
0
10
0
2014
5
8
2
4
2
2015
9
2016
Seed grant money was awarded to evaluate use of a new
thromboelastograph device for anticoagulation monitoring
in ECMO.
This year, national and international presentations were given
in California, Hawaii, Michigan, New Jersey, Scotland, China,
Qatar and Scotland. A regional training symposium, hosted by
Inova, is planned for June 2-3, 2017.
2016
Days of Support
605
Hours of Support
14,323
Pediatric ECMO Runs
9
Adult ECMO Runs
57
Total ECMO Runs
66
Contact Us I Refer a Patient:
Cardiac Access Line
Adult Patients: 703.776.5905
Neonatal or Pediatric: 877.900.9543
Transport of patients on ECMO is available.
31
Heart Failure
“Our vision is to be recognized as the highest quality,
destination program for advanced heart failure care
in the region and to be nationally recognized for
innovative and quality care.”
Shashank Desai, MD, MBA
Shashank Desai, MD
Medical Director, Advanced Heart Failure/Transplant
Program, Inova Heart and Vascular Institute
Mechanical Circulatory Support
Inova’s IHVI physicians have been at the forefront of medical
advances in treating heart failure – from initial symptoms and
medical therapy to advanced heart failure therapies.
Ventricular Assist Devices
32
Expertise and Innovation in VAD/LVAD
IHVI is one of the busiest ventricular assist programs in the
Mid-Atlantic and has earned The Joint Commission’s Advanced
Certification for exemplary quality care and service for its VAD
program. We are a leader in development and use of VAD/LVAD
for patients living with end-stage heart failure – whether awaiting
a transplant or as a permanent therapy providing improved quality
of life and increased time to live.
For more than 20 years, we have participated in research to
develop improved devices for both bridge-to-transplant and
destination therapy. Our research activity continues with an
expanding range of studies – visit inovaheart.org/research
Shock Team
Ramesh Singh, MD
Behnam Tehrani, MD
Alex Truesdell, MD
Research studies:
inovaheart.org/research
“We are committed to providing any and all
therapies in the treatment of advanced heart
failure particularly with the priority of improving
the quality of life for our patients.”
VAD Volumes
80
70
61
58
60
51
Ramesh Singh, MD, FACS
50
40
Ramesh Singh, MD
Surgical Director, Mechanical
Circulatory Support Program
30
20
Remote Monitoring
10
0
2015
2014
2016
2015 Heart Failure Outcomes
25
21.4%
22%
IFMC
National
Average
20
15
10.8%
11.6%
10
5
0
Readmission
Mortality
Home-based Monitoring Enables More Precise
Medication Management
Heart failure patients frequently experience complications
such as fluid backing up in their lungs that result
in repeated hospitalizations. Traditional outpatient
management has proven to be limited in its ability to
prevent these types of problems. Inova has reached
beyond simply caring for heart failure patients with
intermittent office visits to helping manage people while at
home through the use of implantable technologies.
The remote monitoring program was developed as
an adjunct to Inova’s expert advanced heart failure
management services. Since the FDA’s approval of
CardioMEMS™ in early 2016, IHVI has utilized this new
technology. It is a sensor, about the size of a paperclip,
inserted into the pulmonary artery during a minimally
invasive, outpatient procedure. The device continuously
measures pressure inside the artery and automatically
sends results to a patient’s physician. This allows
medication to be immediately adjusted to help prevent
heart failure decompensation and thus help prevent urgent
admissions to the hospital.
CardioMEMS™ is the only FDA-approved heart failure
monitoring system.
Recent trials demonstrated:
• 37% reduction in hospital admissions
• 78% reduction in re-admissions within 30 days
post-discharge
• 98.6% of patients free of complications
CardioMEMS™ HF System
(Photo courtesty of St. Jude Medical Inc.)
Contact Us I Refer A Patient
Cardiac Access
Adult: 703.776.5905
Pediatric: 877.900.9543
33
Heart Transplantation
“Inova’s heart transplant team is committed
to furthering the growth of the program by
engaging in clinical trials with the newest
technologies as well as building on our
strong foundations and core abilities that
have kept our outcomes solid.”
Linda J. Bogar, MD
Linda J. Bogar, MD FACS, FACC
Surgical Director
Heart and Lung Transplant Programs
Our growing program serves a large proportion of the
population in the Northern Virginia/Maryland/DC area and
beyond. Our success is due to multiple expert disciplines
involved in caring for each patient as well as our depth of
options from our advanced heart failure team.
34
Heart Transplant Volumes
30
27
25
22
18
20
15
10
5
0
2015
2014
2016
One Year Patient Survival - 55 patients
7/1/13 through 12/31/15
90.91%
Observed:
Expected:
Hazard Ratio:
88.59%
0.87%
Contact Us I Refer A Patient
703.776.7697
Deirdre Carolan, RN, Eva Baisey and Edward Lefrak, MD
30
th
In December 2016, IHVI celebrated the 30th anniversary of the first heart transplant for the DC metropolitan
region, a milestone achievement. Our first patient, Eva Baisey, is one of only a handful of heart transplant
recipients who have survived longer than 25 years. Eva remains a vibrant and joyful person who relished the
opportunity to catch up with her surgeon, Edward Lefrak, MD, during an interview with The Washington Post.
She also spent time with two of the nurses who were central to her care and recovery, former OR nurse Mary
Dellinger and Deirdre Carolan, who served as her primary nurse during the months long recovery process and
has remained part of her annual check-ups. Read the full feature story at inovaheart.org/firstheart
35
35
Eva Baisey and Edward Lefrak, MD - 30 years ago.
Cardiac Rehab
36
Inova Heart and Vascular Institute’s comprehensive
cardiac rehabilitation program is the only program
in the Washington, DC metro area certified
for 22 years by the American Association of
Cardiovascular and Pulmonary Rehabilitation for
adherence to rigorous national standards and
guidelines. With locations across Northern Virginia,
patients have access to a complete, personalized
heart-disease management program close to home
and work.
“The value of cardiac
rehabilitation is increasingly
being recognized. Evidence of
that is Medicare’s emphasis on
patient participation. We help
people who have experienced a
cardiac event not only return with
Robert Shor, MD
confidence to their daily lives but
also to modify their lifestyles and fitness habits to
support a healthier future.”
New congestive heart failure guidelines from
CMS open the benefits of cardiac rehab to a
broader array of patients including heart attack,
coronary bypass, valve surgery, and stent/angioplasty for angina.
Robert Shor, MD, FACC
The Cardiac Rehabilitation Program at Inova
Fairfax Medical Campus has been certified by
the American Association of Cardiovascular and
Pulmonary Rehabilitation (AACVPR) since 1995.
Inova Mount Vernon and Inova Loudoun hospitals
are also currently certified. This peer-review
accreditation process recognizes leaders in the
field of cardiovascular and pulmonary rehabilitation
offering the most advanced practices available.
Medical Director, Cardiac Rehabilitation
Cardiac Rehabilitation
Patients
Excercise Sessions
2014
3,428
22,387
2015
3,771
24,576
2016
4,189
27,722
Learn about cardiac rehabilitation
from a patient’s perspective, visit
Inovaheart.org/video/patricia
Women and Heart Disease
Comprehensive Care, Prevention
and Research
In 2016, Inova opened a Women’s Comprehensive
Health Center that includes a focus on assessing
and managing women’s unique cardiovascular
needs. Services include coordinated, multidisciplinary care for a wide range of
cardiovascular conditions:
• Prevention cardiology
The center also focuses on implementing
personalized risk assessment and early screening
for women with traditional and female-specific
risk factors.
The center intends to recruit more women
to participate in cardiovascular clinical trials.
Nationally, women comprise only 30% of study
participants. Expanded participation in research
should help improve outcomes for women with
heart disease.
• Pregnancy and heart disease
“Symptoms can vary greatly in women,
which can lead to missed diagnoses and
under-treatment. Women are more likely
to have subtle symptoms – and early
recognition of these more subtle symptoms
is vital.”
• Ischemic heart disease
• Structural heart disease
• Cardio-oncology
• Peri-partum cardiomyopathy
Contact Us I Refer A Patient
Inova Women’s Comprehensive Health Center
571.665.6430
Kelly Epps, MD
Kelly Epps, MD, MSHP, FACC
Interventional Cardiologist
Director, Women’s Cardiovascular Health Center
Inova Women’s Comprehensive Health Center
Inova Heart and Vascular Institute
Center for Learning and Innovation
Vision:
To provide the most interactive and innovative
educational opportunities available, and to be
recognized by our peers and the community
as the world leader in cardiovascular continuous
medical education.
Mission:
Lead – Identify educational needs and create
a platform for healthcare providers and leaders
from around the world to share and discuss new
developments and advanced clinical practices in
cardiovascular medicine.
Innovate – Advance the field of cardiovascular
medicine through education and awareness
about health and cardiovascular disease in
the community we serve.
Sustain – Educate current and future healthcare
professionals.
2015 – 2016
20 CME course offerings
1,500 (1,200 clinical staff) learners
19 States represented by registrants
“By combining the resources of the varied
disciplines of IHVI specialists and world
renowned guest speakers, we provide an
unprecedented expert forum to improve patient
care by addressing the educational needs of
all healthcare providers who care for patients
with cardiovascular disease.”
Merdod Ghafouri, DO, FACC, FAHA
Chief Patient Experience Officer, IHVI
Director, Inova Center for Learning and Innovation
Publications and Research
For a list of published articles,
visit inovaheart.org/publications
Special Acknowledgement
PFAC members
Joe Knotts
Steve Koth
Antonio Benedi
Michael Kolansky
Kevin Houlihan
Margie Benjamin
Cindy McElroy
Elicia Pierno
Chet Kessler, MD
Marc Busman
Christopher Thayer
Patricia Schwartz
IHVI PFAC Committee Leadership
Merdod Ghafouri, DO
Heather Russell
Cynthia Mowery
Leila Elliott
Outcomes Team
Kristen Eimer
Marian Hartle
Linda Halpin
Donna Soper
Paul Gentile
Bret Gallardo
Terrie Wilson
Julia Streich
Additional Outcomes Support
Beth Suddaby
Pam West
Steve Ives
Mark McDowell
Christy Mazzaroti
Pat Murphy
Nancy Morrissey
Christy Schatz
37
Inova Heart and Vascular Physicians
Advanced Heart Failure
Lauren Cooper, MD
Shashank Desai, MD
Christopher May, MD
Gurusher Panjrath, MD
Palak Shah, MD
Advanced Lung Disease and
Transplant Program Whitney Brown, MD
Christopher King, MD
Steven Nathan, MD
Oksana Shlobin, MD
Nargues Weir, MD
Cardiac Surgery
Linda Bogar, MD
Lucas Collazo, MD
Kathleen Petro, MD
Liam Ryan, MD
Eric Sarin, MD
Ramesh Singh, MD
Alan Speir, MD
38
Cardiology/Cardiovascular
Disease
Tarek Abou-Ghazala, MD
Khalid Abousy, MD
Marjaneh Akbari, MD
Muhammad Ali, MD
Ather Anis, MD
Aysha Arshad, MD
Walter Atiga, MD
Tariq Aziz, MD
Nicholas Balaji, MD
Michael Banihashemi, MD
Subash Bazaz, MD
Casey Benton, MD
Kambeez Berenji, MD
Rachel Berger, MD
Steven Berman, MD
George Besch, MD
Carl BonTempo, MD
Kenneth Brooks, MD
Christine Bussey, MD
Dean Carpousis, MD
Felix Castro, MD
Anthony Chang, MD
Tania Chao, MD
Asad Chaudhry, MD
Marilyn Chengot, MD
Keith Chu, MD
Mariano Chutuape, MD
Lauren Cooper, MD
Nicholas Cossa, MD
Robert Cunnion, MD
Anna Czajka, MD
Stephen Day, MD
Christopher deFilippi, MD
Shashank Desai, MD
Paul DiLorenzo, MD
Thien Do, MD
James Duc, MD
Sarfraz Durrani, MD
Zayd Eldadah, MD, PhD
Kelly Epps, MD
Timothy Farrell, MD
Adam Fein, MD
Michael Flanagan, MD
Cleveland Francis, MD
Ted Friehling, MD
Rajat Garg, MD
Nadim Geloo, MD
Merdod Ghafouri, DO
Mohammad Ghazvini, MD
Brian Glick, MD
John Golden, MD
Michael Goldman, MD
Mardi Gomberg-Maitland, MD
Paul Gurbel, MD
Tariq Haddad, MD
Afsane Haddad-Mashad, MD
Richard Hart, MD
Seyed Hashemi, MD
Edward Howard, MD
Denise Hurst, MD
Leonard Ilkhanoff, MD
Jeffrey Jackman, MD
Ahsan Jafir, DO
Laurance Kam, MD
Charanjit Khurana, MD
Jospeh Kiernan, MD
Albert Kim, MD
Bhanumathi Krishnan, MD
Sara Kulangara, MD
Sung Lee, MD
Roy Leiboff, MD
Warren Levy, MD
Yaning Liu, MD
Jeffrey Luy, MD
Shahryar Mafi, MD
Alirez Maghsoudi, MD
Carey Marder, MD
Christopher May, MD
Robert McSwain, MD
Stuart Meyers, MD
Lawrence Miller, MD
Azita Moalemi, MD
Jason Morda, MD
Mehrdad Mostaan, MD
Alfred Myaing, MD
Sunil Nachnani, MD
Pradeep Nayak, MD
Minh Van Ngo, MD
Michael Notarianni, MD
John O’Brien, MD
Paul O’Brien, MD
Christopher O’Connor, MD
Susan O’Donoghue, MD
Gurusher Panjrath, MD
Antonio Parente, MD
David Park, MD
Young Park, MD
Dhaval Patel, MD
Richard Perrin, MD
Paula Pinell-Salles, MD
Edward Platia, MD
Dean Pollock, MD
Ashok Prasad, MD
Vikram Prasanna, MD
Jun Quion, MD
Prithviraj Rai, MD
Narian Rajan, MD
Gautam Ramakrishna, MD
Devanhalli Ramaswamy, MD
Haroon Rashid, MD
Archana Reddy, MD
Kevin Rogan, MD
Arnold Rosenblatt, MD
Stephen Rosenfeld, MD
Lawrence Rubin, MD
Anne Safko, MD
Sudip Saha, MD
Chirag Sandesara, MD
Pamela Sears-Rogan, MD
Manish Shah, MD
Neel Shah, MD
Palak Shah, MD
Syed Shahab, MD
Robert Shapiro, MD
Rishabh Sharma, MD
Jennifer Shea, MD
Stuart Sheifer, MD
Mazhar Sheikh, MD
Harvey Sherber, MD
Matthew Sherwood, MD
Robert Shor, MD
Padma Shukla, MD
Balbir Sidhu, MD
James Sipes, MD
Tseday Sirak, MD
Tina Slottow, MD
Rahsaan Smith, MD
Adam Strickberger, MD
David Strouse, MD
Anne Summers, MD
Hamid Taheri, MD
Mark Tanenbaum, MD
Naghmeh Tebyanian, MD
Behnam Tehrani, MD
Athanasios Thomaides, MD
Henry Tran, MD
Ketan Trivedi, MD
Alexander Truesdell, MD
Constantine Tziros, MD
Ganesh Venkataraman, MD
Kinda Venner-Jones, MD
Ajay Virmani, MD
Mark Vives, MD
Timothy Welch, MD
Marc Wish, MD
Jonathan Yager, MD
Shahram Yazdani, MD
Kambiz Yazdani-Najafabadi, MD
Rafiq Zaheer, MD
Qiong Zhao, MD, PhD
Chief Safety Officer
Charles Murphy, MD
ECMO Program Directors
Heidi Dalton, MD
Charles Murphy, MD
Electrophysiology
Aysha Arshad, MD
Walter Atiga, MD
Anthony Chang, MD
James Duc, MD
Sarfraz Durrani, MD
Zayd Eldadah, MD, PhD
Adam Fein, MD
Ted Friehling, MD
Mohammad Ghazvini, MD
Denise Hurst, MD
Leonard Ilkhanoff, MD
Sung Lee, MD
Robert McSwain, MD
Susan O’Donoghue, MD
Edward Platia, MD
Haroon Rashid, MD
Chirag Sandesara, MD
Manish Shah, MD
Adam Strickberger, MD
David Strouse, MD
Athanasios Thomaides, MD
Ganesh Venkataraman, MD
Marc Wish, MD
Interventional Cardiology
Tarek Abou-Ghazala, MD
Khalid Abousy, MD
Marjaneh Akbari, MD
Ather Anis, MD
Nicholas Balaji, MD
Kambeez Berenji, MD
George Besch, MD
Felix Castro, MD
Mariano Chutuape, MD
Nicholas Cossa, MD
Stephen Day, MD
Paul DiLorenzo, MD
Kelly Epps, MD
Rajat Garg, MD
Nadim Geloo, MD
John Golden, MD
Paul Gurbel, MD
Afsane Haddad-Mashad, MD
Seyed Hashemi, MD
Edward Howard, MD
Ahsan Jafir, DO
Charanjit Khurana, MD
Jospeh Kiernan, MD
Albert Kim, MD
Warren Levy, MD
Stuart Meyers, MD
Lawrence Miller, MD
John O’Brien, MD
Antonio Parente, MD
Richard Perrin, MD
Dean Pollock, MD
Vikram Parsanna, MD
Prithviraj Rai, MD
Narian Rajan, MD
Kevin Rogan, MD
Palak Shah, MD
Syed Shahab, MD
Matthew Sherwood, MD
Balbir Sidhu, MD
Tina Slottow, MD
Rahsaan Smith, MD
Hamid Taheri, MD
Behnam Tehrani, MD
Alexander Truesdell, MD
Ajay Virmani, MD
Shahram Yazdani, MD
Kambiz Yazdani-Najafabadi, MD
Rafiq Zaheer, MD
Interventional Pulmonology
Amit Mahajan, MD
Pediatric Cardiac Surgery
Marcelo Cardarelli, MD
Lucas Collazo, MD
Richard Jonas, MD
Pranava Sinha, MD
Pediatric Cardiology
Hasan Abdallah, MD
Annette Ansong, MD
Margaret Bell Fischer, MD
Alan Benheim, MD
Charles Berul, MD
Patrick Callahan, MD
Sarah Chambers, MD
Amir Dangol, MD
Ted Friehling, MD
Wali Gauvin, MD
Georgios Hartas, MD
Jared Hershenson, MD
Sharon Karr, MD
William Kirby, MD
Jennifer Lindsey, MD
Mohamed Mardini, MD
Jeffrey Moak, MD
Jennifer O’Neil, MD
Jin Park, MD
Harish Rudra, DO
Elizabeth Sherwin, MD
Christopher Talluto, MD
Sherif Tawfik, MD
Kalpana Thammineni, MD
James Thompson, MD
Pediatric Electrophysiology
Charles Berul, MD
Ted Freihling, MD
Jeffery Moak, MD
Elizabeth Sherwin, MD
Thoracic Surgery
Hiran Fernando, MD
Sandeep Khandhar, MD
Paul Kiernan, MD
39
Inova Heart and Vascular Physicians
Vascular and
Interventional Radiology
Reginald Baker, MD
Paul Butros, MD
James Cooper, MD
Alain Drooz, MD
Allen Joseph, MD
Michael Karnaze, MD
Hong Lim, MD
Salman Mufti, MD
Dimitrios Papadouris, MD
Kenneth Rholl, MD
David Spinosa, MD
Keith Sterling, MD
Venu Vadlamudi, MD
Arina Van Breda, MD
Jay Varma, MD
Vascular Surgery
Behdad Aryavand, MD
Maseer Bade, MD
Kapil Gopal, MD
Homayoun Hashemi, MD
Ahmed Kayssi, MD
James Laredo, MD
Dipankar Mukherjee, MD
Richard Neville, MD
Bao-Ngoc Nguyen, MD
Reagan Quan, MD
Rodeen Rahbar, MD
IHVI Physician Leadership Development
Program
Building physician leadership is an important priority for IHVI. Working through the American
Association for Physician Leadership, and under the direction of Christopher O’Connor, MD and
Warren Levy, MD, a leadership development program that includes didactic sessions, individual
mentoring and a capstone project is now underway with eighteen IHVI physicians actively
participating. Recent sessions have focused on finance, quality and organizational leadership.
A second cohort will have the opportunity to participate in the fall of 2017.
40
Inova is a global leader in personalized health, which
leverages precision medicine to predict, prevent and
treat disease, enabling individuals to live longer,
healthier lives. At Inova, we serve more than 2 million
people each year from throughout the Washington, DC
metropolitan area and beyond.
Inova At A Glance - 2016
1,780
101,728
108,113
419,532
427,483
Inpatient
Admissions
Beds
Home Care Visits
Outpatient
Referred Visits
6,190
ER Visits
Affiliated
Physicians
We are shaping the future of health through our integrated
network of hospitals, primary and specialty care practices,
emergency and urgent care centers, outpatient services and
destination institutes. Our commitment to health and wellness
is further reflected in our sustainable practices. Inova is home
to world-class researchers, expert medical specialists and
renowned scientists, who are driving innovation to improve
patient care, prevent disease and promote wellness.
For more information, visit inova.org, or find us on Facebook,
Twitter and LinkedIn.
Cardiac Access
19,765
Births
24/7 Admission. Transfer. Specialized Transport.
150+
Service Sites
Adult Patients: 703.776.5905
Pediatric Patients: 877.900.9543
G35493/3-17/15,500